Following WHO approval for programmatic use of typhoid Vi-conjugate vaccines (TCVs) in endemic countries, Gavi, the Vaccine Alliance, pledged its support to enable the introduction of these vaccines in 54 low-income and middle-income countries. Joke Bilcke and colleagues used a modelling approach to identify optimal strategies that would enable an average net benefit and the epidemiological conditions under which vaccination using TCVs is optimal. Overall, their Article reveals crucial findings that can guide decision makers on the use of TCVs in typhoid-endemic nations. However, errors on some of the variables that were used in the economic and transmission-dynamic models could substantially alter the conclusions.
Click here to read the article, published in The Lancet.